HCA Healthcare, Inc. (BVMF:H1CA34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 421.28B -13.2% |
| Revenue (ttm) | 398.50B +6.7% |
| Net Income | 35.44B +17.6% |
| EPS | 151.65 +29.4% |
| Shares Out | n/a |
| PE Ratio | 11.89 |
| Forward PE | 12.43 |
| Dividend | 0.54 (0.55%) |
| Ex-Dividend Date | Jun 15, 2026 |
| Volume | 11 |
| Open | 99.18 |
| Previous Close | 95.05 |
| Day's Range | 98.31 - 99.18 |
| 52-Week Range | 91.10 - 143.06 |
| Beta | 1.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 24, 2026 |
About HCA Healthcare
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. The company owns, manages, and operates hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, as well as rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers, and various other facilities. Its general and a... [Read more]
Financial Performance
In 2025, HCA Healthcare's revenue was $75.60 billion, an increase of 7.08% compared to the previous year's $70.60 billion. Earnings were $6.78 billion, an increase of 17.78%.
Financial numbers in USD Financial StatementsNews
HCA Healthcare price target lowered to $369 from $428 at Wells Fargo
Wells Fargo analyst Stephen Baxter lowered the firm’s price target on HCA Healthcare (HCA) to $369 from $428 and keeps an Equal Weight rating on the shares. The firm notes…
HCA Healthcare price target lowered to $402 from $427 at Barclays
Barclays lowered the firm’s price target on HCA Healthcare (HCA) to $402 from $427 and keeps an Equal Weight rating on the shares. The company’s 2026 guidance seems to imply…
HCA preannouncement negative for Quest, Labcorp, says Barclays
Barclays views HCA Healthcare’s (HCA) preannouncement on Affordable Care Act coverage lost during Q2 is a negative read-through for Quest Diagnostics (DGX) and Labcorp (LH). HCA’s Affordable Care Act ...
HCA Healthcare price target lowered to $370 from $435 at BofA
BofA lowered the firm’s price target on HCA Healthcare (HCA) to $370 from $435 and keeps a Neutral rating on the shares. HCA cut its EBITDA guidance by 2% on…
HCA Healthcare price target lowered to $435 from $534 at RBC Capital
RBC Capital lowered the firm’s price target on HCA Healthcare (HCA) to $435 from $534 and keeps an Outperform rating on the shares. With shares trading off 7% following the…
HCA Healthcare price target lowered to $450 from $525 at Jefferies
Jefferies lowered the firm’s price target on HCA Healthcare (HCA) to $450 from $525 and keeps a Buy rating on the shares. While the firm says it understands the HCA…
HCA Healthcare guidance cut likely to trigger selloff, says Cantor Fitzgerald
HCA Healthcare (HCA) cut 2026 EBITDA guidance due to worsening payor mix despite DPP benefits, likely triggering a sharp stock selloff and weighing on healthcare peers as results fell short…
HCA Healthcare Stock Falls as Uninsured Patients and Declining Surgeries Dent Outlook
HCA Healthcare stock falls after the hospital chain operator lowers its full-year profit outlook as uninsured patients rise in the second quarter.
HCA Healthcare Shares Drop After Quarterly Earnings Squeezed by Payer Mix Shifts
The for-profit operator of healthcare facilities scaled back financial guidance for the year following payer mix shifts due to health insurance exchanges.
HCA reports preliminary quarterly revenue above expectations
HCA Healthcare on Tuesday reported preliminary second-quarter revenue above Wall Street expectations.
HCA Healthcare sees Q2 EPS $7.62, consensus $7.47
Sees revenue $20.23B, consensus $19.38B. For the second quarter of 2026, Adjusted EBITDA is expected to approximate $4.027B, compared to $3.849B in the second quarter of 2025. Same facility admissions...
HCA Healthcare lowers FY26 EPS view $28.70-$30.50 from $29.10-$31.50
Consensus $30.19. Narrows revenue view $77B-$79.5B from $76.5B-$80B, consensus $78.58B. Lowers adjusted EBITDA view $15.4B-$16.1B from $15.55B-$16.45B.
HCA Healthcare, Inc. 2nd Quarter 2026 Earnings Conference Call
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) announces the following Webcast: What: HCA Healthcare, Inc. 2Q 2026 Earnings Call When: Friday, July 24, 2026, at 9:00 AM Central (1...
HCA Healthcare Previews Second Quarter 2026 Results
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced preliminary financial and operating results for the second quarter ended June 30, 2026. The preliminary financial an...
HCA Healthcare price target lowered to $475 from $510 at KeyBanc
KeyBanc lowered the firm’s price target on HCA Healthcare (HCA) to $475 from $510 and keeps an Overweight rating on the shares. Healthcare utilization continued to moderate through the first…
HCA Healthcare price target lowered to $428 from $436 at Wells Fargo
Wells Fargo lowered the firm’s price target on HCA Healthcare (HCA) to $428 from $436 and keeps an Equal Weight rating on the shares. The firm’s outlook for Healthcare Services…
HCA Healthcare downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded HCA Healthcare (HCA) to Equal Weight from Overweight with a price target of $427, down from $496. Following a strong three-year bull run driven by ACA membership growth,…
HCA Healthcare price target lowered to $525 from $588 at Cantor Fitzgerald
Cantor Fitzgerald lowered the firm’s price target on HCA Healthcare (HCA) to $525 from $588 and keeps an Overweight rating on the shares. Cantor prefers payors over providers heading into…
HCA Healthcare announces research published in NEJM on CRISPR-based therapy
HCA Healthcare (HCA) announced new research published in The New England Journal of Medicine, NEJM, demonstrating promising results from a gene-editing therapy being investigated in children ages 5-11...
HCA Healthcare Announces New England Journal of Medicine Study Highlighting Advances in CRISPR-based Therapy for Children
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced new research published in The New England Journal of Medicine (NEJ...
HCA Healthcare price target lowered to $431 from $500 at TD Cowen
TD Cowen analyst Ryan Langston lowered the firm’s price target on HCA Healthcare (HCA) to $431 from $500 and keeps a Buy rating on the shares. The firm reduced the…
Mission Bio and Human Cell Atlas Collaborate to Expand Access to Single-Cell Multiomics Ahead of HCA 2026 Meeting
SAN FRANCISCO--(BUSINESS WIRE)--Mission Bio, the leader in single-cell multiomics solutions, today announced a collaboration with the Human Cell Atlas (HCA), a global consortium working to create comp...
Vizgen® to Advance Cell Atlases with New Volumetric Tissue Mapping Spatial Data and Services at HCA 2026 Meeting
WALTHAM, Mass.--(BUSINESS WIRE)-- #HCA--Vizgen, Inc., a leader in spatial multiomics and developer of the MERSCOPE Ultra™ Platform, today announced it will debut a 3D Volumetric Tissue Mapping dataset...
HCA Healthcare Announces Agreement to Acquire The College of Health Care Professions
NASHVILLE, Tenn. & HOUSTON--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, and The College of Health Care Professions (CHCP), one of the largest al...
HCA Healthcare Transcript: RBC Capital Markets Global Healthcare Conference 2026
Management reaffirmed a $600M–$900M EBITDA headwind from APTC expiration, with Q1 tracking at the lower end. Operational improvements and a $400M resiliency program are on track, while capital deployment and acquisitions focus on outpatient growth. DT&I investments continue, and policy changes are seen as manageable.